Biocryst patents expiration
1. Orladeyo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(11 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 3, 2027 |
| New Chemical Entity Exclusivity (NCE) | Dec 3, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 2024-12-03
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and ped...
Dosage: CAPSULE;ORAL
ORLADEYO family patents
2. Rapivab patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(3 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(3 years from now) | |
Drugs and Companies using PERAMIVIR ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adult...
Dosage: SOLUTION;INTRAVENOUS
RAPIVAB family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic